bevacizumab与ranibizumab治疗新生血管性眼病的疗效及安全性的meta分析

Bevacizumab与Ranibizumab治疗新生血管性眼病的疗效及安全性的Meta分析作者：麻南，贺翔鸽，MANan，HEXiang-ge作者单位：麻南,MANan(北京解放军第三○六医院眼科)，贺翔鸽,HEXiang-ge(第三军医大学大坪医院眼科,重庆,400042)刊名：中华眼科杂志英文刊名：CHINESEJOURNALOFOPHTHALMOLOGY年，卷(期)：2010，46(3)被引用次数：0次参考文献(15条)1.MichelsS.RosenfeldPJ.PuliafitoCASystemicbevacizunmb(Avastln)therapyforneovascuarage-relatedmaculardegenerationtwelve-weekresultsofanuncontrolledopen-labelclinicalstudy20052.PatelPJ.BunceC.TufailAArandomized,double-maskedphaseⅢ/ⅣstudyoftheefficacyandsafetyofAvastin(R)(Bevacizumab)intravitrealinjectionscomparedtostandardtherapyinsubjectswithchoroidalneovascularisationsecondarytoage-relatedmaculardegeneration:clinicaltrialdesign20083.YazdaniS.HendiK.PakravanMIntravitrealbevacizumabforneovascularglaucoma:arandomizedcontrolledtrial20094.JadadAR.MooreRA.CarrollDAssessingthequalityofreportsofrandomizedclinicaltrials:isblindingnecessary?19965.GennadyL.AmdeW.DeshiVComparativeStudyofIntravitrealBevacizumab(Avastin)versusRanibizumab(Lucentis)inthetreatmentofneovascularage-relatedmaculardegeneration20096.SophieB.RiscoM.EdwardsAOBilateralsimultaneousintravitrealinjectionsintheofficesetting20097.WolfA.KookD.StraussRHowtotreatrecurrencesafterAvastintreatmentforneovascularAMD:sticktoAvastinorswitchtoLucentis?20088.ValmaggiaC.HaueterI.KloosPThetreatmentofchoroidalneovascularizationsinage-relatedmacuhrdegenerationusingeitherAvastinorLucentis20099.HanDP.McAllisterJT.WeinbergDVCombinedintravitrealanti-VEGFandverteporfinphotodynamictherapyforjuxtafovealandextrafovealchoroidalneovascularizationasanalternativetolaserphotocoagulation200910.ShahAR.DelPrioreLVDurationofactionofintravitrealRanibizumabandBevacizumabinexudativeamdeyesbasedonmacularvolumemeasurements200911.LadasID.KaragiannisDA.RouvasAASafetyofrepeatintravitealinjectionsofbevacizumabversusranibizumab:ourexperienceafter2000injections200912.LaidlawDA.AbbottA.ResserDADevelopmentofaclinicallyfeasiblelogMARalternativetotheSnellenchart:performanceofthecompactreducedlogMARvisualacuitychartinamblyopicchildren200313.CursiefenC.ChenL.BorgesLPVEGF-Astimulateslymphangiogenesisandhemangiogenesisininflammatoryneovascularizationviamacrophagerecruitment200414.ColquittJL.JonesJ.TanSCRanibizumabandpegaptanibforthetreatmentofage-relatedmaculardegeneration:asystematicreviewandeconomicevaluation200815.Martínez-CarpioPA.Bonafonte-MárquezE.Heredia-GarcíaCDEfficacyandsafetyofintravitrealinjectionofbevacizumabinthetreatmentofneovascularglaucma:systematicreview2008相似文献(2条)1.期刊论文孙晓东.许薇琦.PhilipJ.Rosenfeld.SUNXiao-dong.XUWei-qi.PhilipJ.RosenfeldBevacizumab治疗新生血管性眼病的疗效和安全性-中华眼科杂志2008,44(3)近年来,国外应用Bevacizumab治疗新生血管性眼病取得了良好的效果,受到了眼科界的广泛关注.作为一种效价比较高的药物,Bevacizumab已经被证明不仅具有抗眼部新生血管形成的作用,更能通过降低血管通透性达到抗渗出的效果.因此,有必要就Bevacizumab治疗新生血管性眼病的疗效和安全性进行综述,为玻璃体内注射Bevacizumab治疗新生血管性眼病的科学性、有效性及安全性提供理论依据.(中华眼科杂志,2008,44:281-284)2.期刊论文郑秀海.王曙光.喻智勇.韩本立整合素αvβ3单克隆抗体对人胆管癌肿瘤血管生成的抑制作用-中华实验外科杂志2002,19(5)目的研究整合素αvβ3单克隆抗体抗人胆管癌血管生成的作用.方法将人胆管癌细胞系QBC939细胞接种于鸡胚尿囊膜(CAM)无血管区,给予整和素αvβ3单克隆抗体,观察其对人胆管癌血管生成及肿瘤生长的影响.结果整合素αvβ3单克隆抗体组血管数目在给予抗体后第2～8天均显著低于磷酸盐缓冲液(PBS)对照组(P<0.05),光镜下瘤细胞分布稀疏,瘤组织新生血管腔减少.结论整合素αvβ3单克隆抗体能够抑制胆管癌新生血管的生成,具有显著的抗肿瘤作用.本文链接：http://d.g.wanfangdata.com.cn/Periodical_zhyk201003014.aspx授权使用：上海海事大学(wflshyxy)，授权号：2412c4ae-49a1-4b04-91e6-9e23016b7663下载时间：2010年11月3日